Mark Day
Director/Board Member at Aeromics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Deborah Rathjen | M | - | 7 years | |
| Jeffrey P. Draime | M | 57 |
Aeromics, Inc.
 Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | 7 years |
| David Wurzer | M | 65 | 6 years | |
| Christopher Lowe | M | 56 | 7 years | |
| Makarand Jawadekar | M | 73 | 4 years | |
| John E. Curran | M | - | 6 years | |
| Theodore Rokita | M | 54 | 4 years | |
| Peter Longo | M | - |
Aeromics, Inc.
Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | 8 years |
| Peter C. Agre | M | - |
Aeromics, Inc.
Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | 5 years |
| Mario David Saltarelli | M | 63 | 6 years | |
| Thomas Zindrick | M | 65 |
Aeromics, Inc.
Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | 6 years |
| Dave Jenkins | M | - |
Aeromics, Inc.
Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | 5 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Brennan | M | 70 | 7 years | |
| Marc F. Pelletier | M | 53 |
Aeromics, Inc.
Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | 12 years |
| Robin Hutchison | M | 68 | 10 years | |
| Stephen P. Squinto | M | 67 | 23 years | |
| Felix Baker | M | 55 | 6 years | |
| James Sapirstein | M | 63 | 2 years | |
| Mahalakshmi Radhakrishnan | M | - | 1 years | |
| Christopher Coughlin | M | 71 | 7 years | |
| Mukund S. Kulkarni | M | 76 | 6 years | |
| Caroline Dircks | M | - | 2 years | |
| Judith F. Dalling | F | 69 | 3 years | |
| J. Hutchison | M | 68 | 9 years | |
| H. Christian Fibiger | M | 80 | 7 years | |
| Catherine London | F | - | - | |
| Gregory Gubitz | M | 66 | 5 years | |
| M. Burns | F | 66 | 4 years | |
| William Keller | M | 75 | 6 years | |
| Ronald Erickson | M | 80 | 7 years | |
| Terry Pearson | M | 78 | 9 years | |
| Max E. Link | M | 84 | 22 years | |
| Nancy E. Stagliano | M | 57 | 2 years | |
| Doug Williams | M | - | - | |
| Caroline Hill | M | - | - | |
| Melissa Manno | F | - | 2 years | |
| Matthew Batters | M | 48 | 4 years | |
| John Michael Hutchison | M | 80 | 6 years | |
| Randy Teel | M | 45 | 2 years | |
| James Loerop | M | 60 | 2 years | |
| Brian Krex | M | 57 | 4 years | |
| Paul R. McGuirk | M | 72 |
Aeromics, Inc.
Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | 11 years |
| Jens Renstrup | M | 59 | 3 years | |
| Martine Zimmermann | M | 55 | 7 years | |
| Thomas-Christian Mix | M | 57 | 2 years | |
| Mohammed Qatanani | M | 50 | 3 years | |
| Jason Meyenburg | M | 47 | 13 years | |
| Behrad Derakhshan | M | 44 | 2 years | |
| Lisa Trivison Beck | F | 62 | 3 years | |
| George Llado | M | 58 | - | |
| Edward Miller | M | 59 | 3 years | |
| John Tilton | M | 56 | 10 years | |
| Saqib Islam | M | 54 | 3 years | |
| Dominique Monnet | M | 65 | 1 years | |
| Reinhard Gabathuler | M | - | - | |
| Henric Bjarke | M | 57 | 5 years | |
| F. Carsten Thiel | M | 61 | 3 years | |
| Stephanie Fagan | F | - | 2 years | |
| Paresh N. Soni | M | 63 | 2 years | |
| Bill Lundberg | M | 60 | 4 years | |
| Jeremy Springhorn | M | 61 | 9 years | |
| Jing Marantz | M | 58 | 2 years | |
| James Engelhart | M | 60 | 2 years | |
| John V. W. Reynders | M | - | 6 years | |
| Julie O'Neill | F | 58 | 3 years | |
| Romesh R. Subramanian | M | 58 | 3 years | |
| Christine Antalik | F | 53 | 2 years | |
| Mittie Doyle | M | 59 | 3 years | |
| Radhika Tripuraneni | M | 44 | - | |
| Al Boyle | M | - | 6 years | |
| Derek Adams | M | 50 | 11 years | |
| Joseph Newell | M | 54 | 2 years | |
| Albert Paszek | M | - | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 73 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Mark Day
- Personal Network
